Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival
The deal will give Genmab control of a midphase antibody-drug conjugate that could compete against AbbVie’s Elahere.
Nick Paul Taylor
Apr 3, 2024 5:32am
AbbVie drops MacroGenics-partnered ADC in light of early data
Mar 8, 2024 8:20am
Firefly Bio assembles with $94M and an ADC dream team
Feb 15, 2024 8:11am
LegoChem, riding ADC sugar rush, raises $411M from sweet maker
Jan 16, 2024 5:49am
Christmas deal spree: See what J&J, Roche had in their stockings
Jan 2, 2024 7:35am
Bristol Myers pays $800M upfront for antibody-drug conjugate
Dec 12, 2023 5:30am